High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age
| Autor: | K, Antman, L, Ayash, A, Elias, C, Wheeler, G, Schwartz, R, Mazanet, I, Tepler, L E, Schnipper, E, Frei |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Adult
Salvage Therapy Age Factors Granulocyte-Macrophage Colony-Stimulating Factor Breast Neoplasms Middle Aged Carmustine Survival Analysis Carboplatin Treatment Outcome Antineoplastic Combined Chemotherapy Protocols Granulocyte Colony-Stimulating Factor Humans Female Neoplasm Metastasis Bone Marrow Diseases Cyclophosphamide Melphalan Thiotepa Bone Marrow Transplantation |
| Zdroj: | Journal of the National Cancer Institute. Monographs. (16) |
| ISSN: | 1052-6773 |
| Popis: | The analysis was undertaken to determine if the time to progression and survival for women with breast cancer treated with high-dose chemotherapy after a conventional-dose induction therapy differs significantly for women younger and older than 40 years of age. All patients treated in phase II or III protocols of high-dose chemotherapy for breast cancer are included in this analysis. Women were treated on one of six protocols: four sequential phase II protocols for metastatic breast cancer involving cyclophosphamide at a dose of 6000 mg/m2, thiotepa at 500 mg/m2, and carboplatin at 800 mg/m2 (CTCb) chemotherapy; one phase II study of CTCb chemotherapy for stage III or inflammatory breast cancer; and a Cancer and Leukemia Group B phase III study of cyclophosphamide, carmustine, and cisplatin for women with more than 10 involved lymph nodes after primary therapy. Eligibility criteria for the patients with metastatic disease included histologically documented breast cancer, at least a partial response to conventional dose therapy, no prior pelvic radiotherapy, cumulative doxorubicin of less than 500 mg/m2, and physiologic age of 18-55 years. Patients with inadequate renal, hepatic, pulmonary, and cardiac function or tumor involvement of marrow or central nervous system were excluded. Of 99 registered patients, three (3%) died of toxicity. There were no toxic deaths in protocols for stage II and III disease, and to date none of these patients have relapsed. Thus, there are no differences by age for these studies.(ABSTRACT TRUNCATED AT 250 WORDS) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|